牛牛AI助理已提取核心訊息
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
Senti Biosciences, a clinical-stage biotechnology company, reported a net loss of $71.1 million for the year ended December 31, 2023, compared to a net loss of $58.2 million for the previous year. The company's cash, cash equivalents, and short-term investments totaled $35.9 million as of December 31, 2023, down from $98.6 million the previous year. Operating expenses for the year were $95.3 million, with research and development expenses accounting for $32.2 million. The company recognized a gain of $21.9 million from the disposal of its Alameda facility to GeneFab, which also resulted in a reduction of longer-term operating expenses. Senti Biosciences has not generated revenue from product sales and anticipates continued significant losses and increased expenses as it advances its gene circuit platform technologies and clinical development of product candidates. The company's future plans include focusing on the clinical development of SENTI-202 and partnering its SENTI-301A program in China with Celest. Senti Biosciences has raised concerns about its ability to continue as a going concern beyond the next twelve months without additional funding.
臨床階段的生物技術公司Senti Biosciences報告稱，截至2023年12月31日的年度淨虧損爲7,110萬美元，而上一年的淨虧損爲5,820萬美元。截至2023年12月31日，該公司的現金、現金等價物和短期投資總額爲3590萬美元，低於去年的9,860萬美元。該年度的運營支出爲9,530萬美元，其中研發費用爲3,220萬美元。該公司確認將其阿拉米達工廠出售給GeneFab獲得了2190萬美元的收益，這也減少了長期運營支出。Senti Biosciences尚未從產品銷售中獲得收入，預計隨着其基因迴路平台技術和候選產品的臨床開發，將繼續出現巨額虧損和支出增加。該公司的未來計劃包括專注於 SENTI-202 的臨床開發，以及與Celest合作在中國的 SENTI-301A 項目。Senti Biosciences對在沒有額外資金的情況下能否在未來十二個月之後繼續作爲持續經營企業表示擔憂。
臨床階段的生物技術公司Senti Biosciences報告稱，截至2023年12月31日的年度淨虧損爲7,110萬美元，而上一年的淨虧損爲5,820萬美元。截至2023年12月31日，該公司的現金、現金等價物和短期投資總額爲3590萬美元，低於去年的9,860萬美元。該年度的運營支出爲9,530萬美元，其中研發費用爲3,220萬美元。該公司確認將其阿拉米達工廠出售給GeneFab獲得了2190萬美元的收益，這也減少了長期運營支出。Senti Biosciences尚未從產品銷售中獲得收入，預計隨着其基因迴路平台技術和候選產品的臨床開發，將繼續出現巨額虧損和支出增加。該公司的未來計劃包括專注於 SENTI-202 的臨床開發，以及與Celest合作在中國的 SENTI-301A 項目。Senti Biosciences對在沒有額外資金的情況下能否在未來十二個月之後繼續作爲持續經營企業表示擔憂。
有用
沒用